DK1516629T3 - Humaniseret anti-CD-11a antibodies - Google Patents

Humaniseret anti-CD-11a antibodies

Info

Publication number
DK1516629T3
DK1516629T3 DK04004941.3T DK04004941T DK1516629T3 DK 1516629 T3 DK1516629 T3 DK 1516629T3 DK 04004941 T DK04004941 T DK 04004941T DK 1516629 T3 DK1516629 T3 DK 1516629T3
Authority
DK
Denmark
Prior art keywords
antibodies
humanized anti
humanized
Prior art date
Application number
DK04004941.3T
Other languages
Danish (da)
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1516629T3 publication Critical patent/DK1516629T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04004941.3T 1996-11-27 1997-10-20 Humaniseret anti-CD-11a antibodies DK1516629T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27
EP97912841A EP0941344B1 (en) 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES

Publications (1)

Publication Number Publication Date
DK1516629T3 true DK1516629T3 (da) 2013-06-03

Family

ID=25046834

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04004941.3T DK1516629T3 (da) 1996-11-27 1997-10-20 Humaniseret anti-CD-11a antibodies
DK97912841T DK0941344T3 (da) 1996-11-27 1997-10-20 Humaniserede anti-CD11a-antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97912841T DK0941344T3 (da) 1996-11-27 1997-10-20 Humaniserede anti-CD11a-antistoffer

Country Status (17)

Country Link
EP (2) EP1516629B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3778945B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100532178B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR008919A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE267257T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU731817C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2272842C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE69729209T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1516629T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2221045T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR04C0028I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL130143A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91122I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300163I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT941344E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1998023761A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA979599B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
US6652855B1 (en) * 1999-03-19 2003-11-25 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
PT1237575E (pt) * 1999-12-14 2008-11-17 Genentech Inc Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
CA2417432C (en) * 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
WO2002057428A1 (en) 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
HUE025101T2 (en) 2002-04-26 2016-02-29 Genentech Inc Purification of proteins other than affinity purification
EP2085096A3 (en) 2002-09-11 2009-08-12 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7619070B2 (en) * 2003-04-23 2009-11-17 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
WO2005079515A2 (en) * 2004-02-19 2005-09-01 The Cbr Institute For Biomedical Research, Inc. Conformation specific antibodies
DE602005018325D1 (de) 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
CA2568570A1 (en) * 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
SI2586788T1 (en) 2007-07-09 2018-07-31 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
MX2010004740A (es) 2007-10-30 2010-05-27 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico.
MX2010011088A (es) * 2008-04-09 2010-11-05 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
DK2848625T3 (da) 2008-08-14 2019-10-07 Genentech Inc Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
CN105037535A (zh) 2008-12-16 2015-11-11 Emd密理博公司 搅拌槽反应器及方法
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
SG178358A1 (en) 2009-08-11 2012-03-29 Genentech Inc Production of proteins in glutamine-free cell culture media
EP2473617B1 (en) 2009-09-01 2020-02-26 F.Hoffmann-La Roche Ag Enhanced protein purification through a modified protein a elution
CA2780549C (en) 2009-11-12 2017-01-03 Vbi Technologies, L.L.C. Subpopulations of spore-like cells and uses thereof
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
TR201905081T4 (tr) 2010-03-22 2019-05-21 Hoffmann La Roche Protein içeren formülasyonların stabilizasyonu için yararlı bileşimler ve yöntemler.
EP2566510A1 (en) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Compositions and methods useful for reducing the viscosity of protein-containing formulations
SG184541A1 (en) 2010-05-17 2012-11-29 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
MX343604B (es) 2010-05-28 2016-11-11 Genentech Inc Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.
JP5894154B2 (ja) 2010-06-24 2016-03-23 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化のためのアルキルグリコシドを含む組成物及び方法
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
KR102067075B1 (ko) 2011-12-22 2020-01-17 제넨테크, 인크. 이온 교환 막 크로마토그래피
CA2866753C (en) 2012-03-27 2020-09-22 Genentech, Inc. Improved harvest operations for recombinant proteins
ES3025360T3 (en) 2012-05-18 2025-06-09 Genentech Inc High-concentration monoclonal antibody formulations
US9393327B2 (en) 2012-12-19 2016-07-19 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
MX375500B (es) 2013-07-09 2025-03-06 Annexon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
WO2015009856A2 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
AU2015287760B2 (en) 2014-07-09 2019-06-20 Genentech, Inc. pH adjustment to improve thaw recovery of cell banks
RS66604B1 (sr) 2014-11-05 2025-04-30 Annexon Inc Humanizovana antitela na faktor komplementa c1q i njihova upotreba
CA2997130A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
SI3353210T1 (sl) 2015-09-25 2025-03-31 F. Hoffmann-La Roche Ag Protitelesa proti TIGIT in postopki uporabe
CN108779171B (zh) 2015-11-24 2022-07-05 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
JP2019510517A (ja) 2016-03-29 2019-04-18 ジェルター， インコーポレイテッド 細胞質内体積に対するペリプラズム体積の比率が０．５：１および１０：１の間にあるグラム陰性細菌におけるタンパク質の発現
CA3044686A1 (en) 2016-12-22 2018-06-28 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
BR112020025623A2 (pt) 2018-07-03 2021-03-23 Bristol-Myers Squibb Company métodos de produção de proteínas recombinantes
EP3864127A1 (en) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Method for membrane gas transfer in high density bioreactor culture
AR118536A1 (es) 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
US11168126B2 (en) 2019-04-12 2021-11-09 Geltor, Inc. Recombinant elastin and production thereof
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
US20230357815A1 (en) 2020-09-22 2023-11-09 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
DK0941344T3 (da) 2004-09-27
EP1516629A2 (en) 2005-03-23
PT941344E (pt) 2004-10-29
EP1516629A3 (en) 2006-09-27
IL130143A0 (en) 2000-06-01
EP1516629B1 (en) 2013-04-03
FR04C0028I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2007-10-26
LU91122I2 (fr) 2005-01-10
AR008919A1 (es) 2000-02-23
DE122004000047I2 (de) 2006-06-14
EP0941344A1 (en) 1999-09-15
EP0941344B1 (en) 2004-05-19
FR04C0028I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-02-11
AU731817B2 (en) 2001-04-05
NL300163I2 (nl) 2005-07-01
KR20000069147A (ko) 2000-11-25
JP2001505425A (ja) 2001-04-24
IL175583A0 (en) 2006-09-05
DE122004000047I1 (de) 2005-04-21
ZA979599B (en) 1999-04-28
CA2272842A1 (en) 1998-06-04
JP2006036779A (ja) 2006-02-09
ATE267257T1 (de) 2004-06-15
DE69729209D1 (de) 2004-06-24
ES2221045T3 (es) 2004-12-16
WO1998023761A1 (en) 1998-06-04
KR100532178B1 (ko) 2005-12-01
JP4309383B2 (ja) 2009-08-05
AU4992997A (en) 1998-06-22
NL300163I1 (nl) 2005-01-03
JP3778945B2 (ja) 2006-05-24
IL130143A (en) 2006-08-01
AU731817C (en) 2001-11-01
CA2272842C (en) 2012-05-15
DE69729209T2 (de) 2005-05-19

Similar Documents

Publication Publication Date Title
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
NO955167D0 (no) Monoklonalt anti-
CY2007012I2 (el) Αντισωματα anti-vegf
IL128406A0 (en) Monoclonal antibodies
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
NO985464D0 (no) Konsentrert antistoffpreparat
DK145493D0 (da) Antistof
DE69622451D1 (de) Funktelefon
DK0837927T3 (da) Anti-CD80-antistoffer
FI965032L (fi) Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
NO981454L (no) Anti-FAS-antistoffer
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
EP0977590A4 (en) HUMAN MONOCLONAL ANTIBODIES
NO20011006D0 (no) Høy-affinitets antistoffer
GB9718911D0 (en) Monoclonal antibodies
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
KR960029102U (ko) 가족 납골묘
BR9609863A (pt) Fecho
BR1100555B1 (pt) anticorpos monoclonais humanizados.
UA10736A (uk) Ћ†љ
GB9615027D0 (en) Monoclonal antibodies
DK0919617T3 (da) Monoklonale antistoffer mod humant MP52